Research (DoD-CPDR) was congressionally mandated and funded in 1991, and began operations in 1992. The programme is a collaborative effort between multiple DoD medical and research facilities, and involves clinicians and basic scientists in clinical, translational and basic science research in prostate cancer.
In the area of prognosis, we are continuing our work with p53 and bcl-2. In particular, a large study of needle biopsies has failed to con®rm the prognostic ability of these biomarkers, unlike our work with radical prostatectomy specimens.
More importantly, we are currently con®rming that focal or clustered p53 staining by immunohistochemistry does represent p53 gene mutations. This work has relied on the laser microdissecting microscope of wholemounted radical prostatectomy cases stained for p53 with focal positive areas con®rmed by automated gene sequencing. Aside from p53, we have discovered a new gene that is only expressed in prostate tissue. Called PCGEM1, this appears to be more prostate-speci®c than PSMA, and encodes an RNA species that may be a riboregulator. CPDR is also involved with SAGE and spectral karyotyping of established prostate cancer cell lines, as well as of new immortalized cell lines derived from radical prostatectomy.
From a treatment perspective, a series of clinical trials are underway for patients with PSA-only recurrence, including Phase II trials of Proscar plus low-dose¯utamide and a Phase III randomized trial of bicalutamide vs placebo. The multicenter longitudinal database has already identi®ed over 10,000 patients, and a long-term goal is to provide a long-term outcome comparison of primary radical prostatectomy versus external beam radiotherapy.
The presentation will provide a brief overview of key new unplublished data from the programme in order to stimulate discussion and opportunities for collaboration.
